Revenue and EPS in Line with Guidance
Q1 revenue of $158.0M, non-GAAP operating income of $9M and non-GAAP diluted EPS of $0.14 — all within the company's guidance ranges.
Large Strategic Orders for Silicon Photonics
Received over $250M in orders for MOCVD, wet processing and SPECTOR Ion Beam Deposition tools to support indium phosphide laser manufacturing; deliveries begin in 2026 with significant ramp expected in 2027 (shipping against orders beginning Q3 2026 with most significant ramp in Q1 2027).
Strong Market Positioning for AI-Driven WFE
Management highlighted differentiation across annealing (LSA/NSA), Ion Beam Deposition, wet processing and MOCVD aligned to AI, HBM, advanced packaging and silicon photonics opportunities; reiterated full-year 2026 revenue guidance of $740M–$800M and non-GAAP diluted EPS $1.50–$1.85.
Capacity Expansion Plans to Meet Demand
Plans to expand SPECTOR IBD capacity ~10x from current base by early 2027 with potential further doubling; expanding wet-processing capacity (onsite and via contract manufacturer) and broader manufacturing footprint expansions to support rising demand and timely deliveries.
Attractive Long-Term Served Available Markets (SAM)
Management projected large SAMs by 2030: annealing $1.3B, IBD/EUV/pellicles $500M, Advanced Packaging $1.0B; compound semi SAMs include indium phosphide lasers $700M, other photonics $550M and GaN Power $250M — supporting multi-year growth narratives.
Positive Near-Term Outlook and Reiterated Guidance
Q2 outlook: revenue $170M–$190M, gross margin 38%–40%, OpEx $52M–$55M, net income $12M–$21M and diluted EPS $0.20–$0.32 (on 64M shares); management reiterated full-year guidance and expects growth to accelerate H2'26 into 2027.
Improving Order Visibility into 2027
Accelerated bookings activity and customer engagements have provided visibility with significant orders and ship schedules extending well into 2027; data storage, advanced packaging and indium phosphide laser orders cited as contributors.